LETTER FROM THE CHAIR
Welcome to the 13th Annual Hematologic Malignancies Demystified: A Critical Appraisal of Data From 2020. We are pleased that you have chosen to attend this educational event. This meeting will provide a comprehensive review of the latest relevant findings reported at the American Society of Hematology (ASH) Annual Meeting and Exposition and other major congresses in 2020. I am confident that the presentations will provide you with a valuable update of practice-changing data that can be readily applied to the clinical management of patients with hematologic malignancies.
Hagop M. Kantarjian, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
(Series Course Director)
Select a date below to view more details.
CME/CE CREDITS AVAILABLE
PART I: [bold]3.0[/bold] | PART II: [bold]2.5[/bold] – [bold]CME/CE[/bold]
Upon completion of this activity, learners will demonstrate: [list]Increased knowledge regarding the - Emerging clinical trial data for hematologic malignancies and disorders - Methods to assess treatment response in patients with hematologic malignancies or disorders - Treatment-related side effects in patients with hematologic malignancies or disorders[/list] [list]Greater confidence in their ability to individualize treatment in patients with hematologic malignancies or disorders [/list]
This educational activity is specifically designed for hematologists/oncologists, nurses, NPs, PAs, and other HCPs who are involved or interested in the management of patients with malignant and nonmalignant hematologic disorders.